CHM.AX up 50.00% to A$0.003 on 18.9M volume after hours 09 Jan 2026: catalyst read
CHM.AX stock jumped 50.00% to A$0.003 on heavy after-hours volume of 18,910,051 shares on 09 Jan 2026. The move came on thin market capitalisation of A$8,217,600 and follows trading that opened at A$0.002 and closed prior at A$0.002. Chimeric Therapeutics Limited (ASX: CHM.AX) is a clinical-stage biotech focused on CAR T and NK cell therapies. Investors pushed the price toward the A$0.009 year high as clinical and liquidity signals drove the high-volume spike.
CHM.AX stock: price action and volume details
Today CHM.AX stock moved from A$0.002 to A$0.003, a 50.00% intraday rise in after hours trading. Volume was 18,910,051, more than double the average daily of 8,332,178, marking this a genuine high-volume mover. The market cap sits at about A$8,217,600, reflecting the share count of 4,108,800,000 outstanding.
CHM.AX stock: catalysts and recent news
Chimeric’s pipeline activity and phase I progress remain the primary catalyst for CHM.AX stock moves. Clinical updates or trial enrolment news can trigger sharp volume spikes in small-cap biotech names. For a broader peer comparison and sector flows, see recent industry data and competitor comparisons on Investing.com source and source.
CHM.AX stock: fundamentals and valuation metrics
Fundamentals show negative earnings with trailing EPS of -0.02 and a reported PE of -0.20. Price averages are A$0.003 (50-day) and A$0.004 (200-day). Key ratios include PB 1.72, P/S 0.90, and current ratio about 0.72, pointing to tight liquidity for a clinical-stage biotech.
CHM.AX stock: technicals and trading indicators
Technicals are mixed. RSI sits near 39.62, indicating mild oversold conditions before today’s spike. Short-term momentum indicators show heavy volatility and a lack of trend (ADX 16.88). Traders should note the stock’s year range A$0.002–A$0.009 for support and resistance.
CHM.AX stock: Meyka grade and analyst context
Meyka AI rates CHM.AX with a score out of 100: 66.03 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The proprietary grade balances clinical upside against thin liquidity and negative earnings. These grades are not guaranteed and we are not financial advisors.
CHM.AX stock: risks, sector context and outlook
Small-cap biotech risk is high for CHM.AX stock given cash burn and trial-stage programmes. Healthcare sector YTD performance is +2.15%, which offers limited shelter versus swings in biotech names. Investors should weigh trial milestone timing, funding needs, and low free float when sizing positions. For the latest quote visit our stock page at Meyka CHM.AX.
Final Thoughts
CHM.AX stock is a classic high-volume biotech mover. Today’s after-hours jump to A$0.003 on 18,910,051 shares shows that clinical news and liquidity shifts still drive outsized moves in small caps. Meyka AI’s forecast model projects A$0.010 over the next quarter, implying a potential upside of 233.33% from A$0.003. A conservative downside target is the year low of A$0.002, implying a -33.33% drop from today’s price. Price targets reflect trial readouts, funding events, and broader healthcare flows. Forecasts are model-based projections and not guarantees. We note tight liquidity, negative EPS -0.02, and a market cap of A$8,217,600. Use position sizing and stop levels when trading CHM.AX stock. Meyka AI is an AI-powered market analysis platform, providing data-driven context but not personal financial advice.
FAQs
What drove the CHM.AX stock spike after hours on 09 Jan 2026?
The after-hours spike was driven by heavy buying around clinical and liquidity signals. CHM.AX stock traded 18,910,051 shares and rose 50.00% to A$0.003, reflecting short-term news interest and low market cap dynamics.
What are realistic price targets for CHM.AX stock?
Near-term upside target from Meyka AI is A$0.010 (quarterly forecast), implying 233.33% upside. A downside support level is A$0.002 (year low), implying -33.33% from today. Targets depend on trial and funding events.
How does CHM.AX stock compare on fundamentals?
CHM.AX stock shows EPS -0.02, PE -0.20, PB 1.72, and price/sales 0.90. These metrics reflect a clinical-stage biotech with negative earnings and constrained liquidity, common in the sector.
When is the next CHM.AX earnings or announcement window?
Earnings or announcement timing lists an upcoming date of 2026-02-26 for company disclosures. Clinical readouts can occur outside formal earnings, and those drive CHM.AX stock volatility.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
